30 results
DEFM14A
ORTX
Orchard Therapeutics plc
16 Nov 23
Proxy related to merger
4:45pm
transactions, 52-week trading range of Orchard ADSs and certain Wall Street equity research analysts’ trading price targets for Orchard ADSs.
Recap … Analysis (25-75th Percentile)
Orchard ADS Price Range During 52-Week Trading Range
Wall Street Equity Research Price Targets
Represents the sum of (i
PREM14A
ORTX
Orchard Therapeutics plc
3 Nov 23
Preliminary proxy related to merger
5:11pm
and acquisition transactions, 52-week trading range of Orchard ADSs and certain Wall Street equity research analysts’ trading price targets for Orchard … Premia Analysis (25-75th Percentile)
Orchard ADS Price Range During 52-Week Trading Range
Wall Street Equity Research Price Targets
Represents
DEFA14A
ORTX
Orchard Therapeutics plc
17 Oct 23
Additional proxy soliciting materials
4:32pm
on Kyowa Kirin proprietary antibody sequences and technologies in certain indications and therapeutic targets.
As engagement around this potential
DEFA14C
ORTX
Orchard Therapeutics plc
5 Oct 23
Additional information
4:43pm
proprietary antibody sequences and technologies in certain indications and therapeutic targets.
As engagement around this potential collaboration progressed
DEFA14A
ORTX
Orchard Therapeutics plc
5 Oct 23
Additional proxy soliciting materials
9:07am
annual rates of base salaries or wages, annual bonus targets or amounts or commissions, nor delayed or deferred payment of any of the foregoing
8-K
EX-2.1
uh8gvda7npmt
5 Oct 23
Kyowa Kirin to Acquire Orchard Therapeutics
9:05am
8-K
EX-99.2
bp0qjm
10 Jan 22
Orchard Therapeutics Announces Recent Commercial and Regulatory Progress for Late-stage HSC Gene Therapy Programs and Outlines Key 2022 Milestones
7:05am
8-K
EX-99.1
jow5hn
12 Nov 20
NOD2 mutation revealed as Crohn’s disease (CD) genetic target, associated with 7-10% of all CD cases in the U.S. and Europe
4:18pm
8-K
EX-99.1
roke7
7 May 20
Orchard Therapeutics Unveils New Strategic Plan and Reports First Quarter 2020 Financial Results
7:03am
DEF 14A
e060oa3k
29 Apr 20
Definitive proxy
4:02pm
PRE 14A
r2mq48
14 Apr 20
Preliminary proxy
4:46pm
POSASR
pawstxvi4ayb 356hbds
28 Feb 20
Automatic shelf registration (post-effective amendment)
12:00am
10-K
6x5a35
27 Feb 20
Annual report
4:02pm